Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

Rhea-AI Summary

Elutia (Nasdaq: ELUT) earned 2026 Great Place to Work Certification, recognizing high-trust culture, sustained engagement, and retention in a regulated, innovation-driven company.

Workforce highlights: women 54% of employees and 62% of leaders, median tenure 6.3 years, half hold advanced degrees, one-third hold doctorates. The release cites prior leadership commercial successes, including an $88 million asset sale and $1.5 billion in products brought to market.

News Market Reaction – ELUT

+4.35%

12 alerts

+4.35% News Effect

+9.1% Peak Tracked

-9.1% Trough Tracked

+$2M Valuation Impact

$56M Market Cap

0.4x Rel. Volume

On the day this news was published, ELUT gained 4.35%, reflecting a moderate positive market reaction. Argus tracked a peak move of +9.1% during that session. Argus tracked a trough of -9.1% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $56M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

EluPro sale: $88 million Women workforce share: 54% Women leadership share: 62% +5 more

8 metrics

EluPro sale $88 million EluPro™ acquired by Boston Scientific

Women workforce share 54% Proportion of Elutia workforce that are women

Women leadership share 62% Proportion of leadership roles held by women

Median tenure 6.3 years Employee median tenure at Elutia

Company age 10 years Time since Elutia was founded

Product sales impact $1.5 billion Sales generated by products Dr. Williams brought to market

Turnover reduction 50% lower Typical turnover in high-trust cultures per Great Place To Work®

Survey research period 30 years Great Place To Work® survey methodology development

Market Reality Check

Price: $1.12 Vol: Volume 467,820 is 1.72x i...

high vol

$1.12 Last Close

Volume Volume 467,820 is 1.72x its 20-day average of 271,356, indicating elevated interest into this culture-focused news. high

Technical Shares at $1.15 are trading below the 200-day MA of $1.35 and 66.76% below the 52-week high of $3.46.

Peers on Argus

ELUT is up 9.52% while sector peers SRTS (-0.52%), CTSO (-0.36%), MDAI (-1.94%),...

1 Down

ELUT is up 9.52% while sector peers SRTS (-0.52%), CTSO (-0.36%), MDAI (-1.94%), TELA (-1.83%) and WOK (-1.97%) are all down, pointing to a stock-specific reaction rather than a sector move.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Prelim Q4 results	Positive	-4.8%	Preliminary Q4 2025 results, debt repayment, and NXT-41x milestone outlook.
Jan 09	Conference presentation	Positive	+4.7%	Presentation on NXT-41x biomatrix at Global BioInnovation Forum.
Nov 06	Q3 earnings & sale	Positive	-5.0%	Q3 2025 results and closing of <b>$88M</b> BioEnvelope sale to Boston Scientific.
Oct 23	Earnings date notice	Neutral	-0.7%	Announcement of Q3 2025 earnings release and conference call schedule.
Oct 14	Investor conference	Positive	+0.9%	CEO presentation and 1x1 investor meetings at LD Micro Main Event XIX.

Pattern Detected

News-driven moves have been mixed: some positive updates saw selloffs, while conference and presentation news more often aligned with modest gains.

Recent Company History

Over the past six months, Elutia has focused on financial strengthening and advancing its NXT-41x program. In Q3 2025 and preliminary Q4 2025, it reported multi-million-dollar net sales and completed an $88M divestiture to Boston Scientific, using proceeds to repay debt and fund NXT-41x. Conference and forum presentations in October 2025 and January 2026 highlighted the biomatrix platform and unmet needs in breast reconstruction. Today’s workplace certification news fits into a broader narrative of building a capable, execution-focused team to support this strategy.

Market Pulse Summary

This announcement highlights Elutia’s certification as a Great Place to Work®, underscoring an exper...

Analysis

This announcement highlights Elutia’s certification as a Great Place to Work®, underscoring an experienced team with a median tenure of 6.3 years, substantial female leadership representation at 62%, and products that have contributed over $1.5 billion in sales historically. In the broader context of recent asset sales and NXT-41x development updates, investors may watch how this strong culture supports execution on upcoming clinical, regulatory, and commercial milestones.

Key Terms

drug-eluting biomatrix, biologic products, breast cancer

3 terms

drug-eluting biomatrix medical

"Elutia Inc. (Nasdaq: ELUT) … a pioneer in drug-eluting biomatrix technologies"

A drug-eluting biomatrix is a medical implant or coating made of biocompatible material that slowly releases a drug at a controlled rate where it is placed in the body, like a sponge that steadily releases medicine into surrounding tissue. For investors, it matters because such technology can improve treatment effectiveness, reduce side effects and repeat procedures, and therefore influence product value, regulatory risk and long-term revenue potential for medical-device and pharmaceutical companies.

biologic products medical

"Over her career she has developed advanced biologic products across multiple therapeutic areas"

Biologic products are medicines and vaccines made from living cells, organisms, or their components rather than simple chemical recipes, more like a handcrafted loaf compared with a mass‑produced cookie. They matter to investors because they are costly and complex to develop and manufacture, protected by strong regulatory rules and exclusivity, and small changes can affect supply, pricing, and long‑term revenue streams for companies.

breast cancer medical

"to improve outcomes for women with breast cancer? Explore Careers - Elutia."

Breast cancer is a disease in which cells in the breast start growing uncontrollably, forming lumps or tumors that can invade nearby tissue or spread elsewhere in the body—like a patch of weeds overtaking a garden if not removed. For investors, breast cancer is important because diagnosis rates, new treatments, drug approvals and clinical trial results can quickly change demand for drugs, diagnostics and care, affecting revenues, valuations and risk for healthcare and related companies.

AI-generated analysis. Not financial advice.

GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work^®, the leading organization that evaluates workplace culture through a standardized, anonymous employee survey methodology developed over 30 years of research. The certification recognizes organizations with high-trust workplace cultures, where sustained engagement and retention support consistent execution in regulated, innovation-driven industries.

“Elutia isn’t for everyone,” said Dana Yoo, PhD, VP of Product Development. “The bar is high, and the work is hard. But the first time I saw our technology used in surgery, I understood why. This wasn’t an experiment. It was someone’s future. It’s demanding, but if you want your work to matter, there’s no place better.” Dr. Yoo has been with Elutia for six years. Over her career she has developed advanced biologic products across multiple therapeutic areas, from orthopedics to wound care, and most recently led the development of EluPro™, which was acquired by Boston Scientific for $88 million.

Elutia’s team is defined by a simple standard: excellence. Elutia hires for intellect and drive, and people stay because of the mission and the team. That commitment is reflected in the depth and stability of the organization. Women comprise 54% of the workforce and 62% of leadership roles. Half of Elutia’s team members hold advanced degrees, and one-third hold doctorates. In a company founded just 10 years ago, a median tenure of 6.3 years reflects continuity throughout the company’s evolution.

“This team executes,” said Fletcher Brehler, Senior Director, Strategic Marketing. “We debate hard, align fast, and move. This isn’t chaos dressed up as innovation. It’s disciplined professionals who know exactly what we’re building and why. That kind of clarity is rare, and it makes even the hardest challenges fun.” Fletcher has been with Elutia for seven years and has been a driving force behind the product launch and success of the SimpliDerm business unit.

“Elutia is special because of the CRU,” said Michelle Williams, PhD, Chief Scientific Officer. “We hold ourselves to uncompromising standards because our patients depend on it. Our mission to humanize medicine so patients can thrive without compromise requires developing first-in-class products and disciplined regulatory execution. It’s hard, but for those who want their efforts to truly matter, Elutia is more than a great place to work. For me, it’s the only place.” Dr. Williams is a co-founder and corporate officer of Elutia and has, over her career, invented and brought products to market that have generated more than $1.5 billion in sales.

Great Place To Work^® is the global authority on workplace culture, employee experience, and leadership behaviors proven to drive market-leading revenue, employee retention, and increased innovation. This data-driven certification identifies high-trust cultures that typically achieve 50% lower turnover and significantly outperform industry benchmarks for performance.

We're hiring!
Want to join a mission-driven CRU of A-players working relentlessly to improve outcomes for women with breast cancer? Explore Careers - Elutia.

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

About Great Place to Work Certification™
Great Place To Work^® Certification™ is the most definitive “employer-of-choice” recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work-Certified.

About Great Place To Work^®
As the global authority on workplace culture, Great Place To Work^® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List.

Investors:
Elutia Investor Relations
ir@elutia.com

FAQ

What does Elutia's 2026 Great Place to Work Certification mean for ELUT investors?

It signals a recognized high-trust workplace culture that can support execution and retention. According to the company, certification reflects sustained engagement and stability that may help operational continuity and product development timelines.

What workforce metrics did Elutia (ELUT) disclose with the 2026 certification announcement?

Elutia reported women comprise 54% of employees and 62% of leadership roles. According to the company, median tenure is 6.3 years; half have advanced degrees and one-third hold doctorates.

Does Elutia (ELUT) cite any commercial track record in the Feb 18, 2026 announcement?

Yes, the company referenced leadership commercial experience, including an $88 million acquisition and $1.5 billion in product sales. According to the company, these examples underscore team experience and execution history.

How might Great Place to Work Certification affect Elutia's (ELUT) hiring and retention?

Certification may improve recruiting and lower turnover by signaling strong culture and engagement. According to the company, high-trust cultures typically show sustained engagement and improved retention supporting consistent execution.

Where can prospective employees learn about careers at Elutia (ELUT) after the certification?

Prospective applicants are directed to explore open roles via Elutia's careers channel. According to the company, they are hiring mission-driven professionals focused on improving outcomes for women with breast cancer.